|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
1,095,971,000 |
Market
Cap: |
19.18(B) |
Last
Volume: |
9,914,068 |
Avg
Vol: |
10,460,039 |
52
Week Range: |
$12.82 - $22.77 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ-100 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Teva Pharmaceutical Industries is a pharmaceutical company. Co. operates through three segments: North America, which includes the U.S. and Canada; Europe, which includes the European Union and certain other European countries; and International Markets, which includes all countries in which Co. operates other than those in Co.'s North America and Europe segments. Co.'s products include: AUSTEDO; AJOVY (anti calcitonin gene-related peptide); COPAXONE; BENDEKA and TREANDA; ProAir HFA; ProAir RespiClick; QVAR; QVAR RediHaler; ProAir Digihaler; ArmonAir Digihaler; AirDuo Digihaler; BRALTUS®; CINQAIR/CINQAERO; and AirDuo RespiClick.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
344,121 |
1,326,860 |
2,037,853 |
2,848,398 |
Total Sell Value |
$6,202,932 |
$23,731,841 |
$35,885,438 |
$46,384,881 |
Total People Sold |
2 |
9 |
10 |
13 |
Total Sell Transactions |
2 |
23 |
29 |
49 |
End Date |
2025-03-16 |
2024-12-13 |
2024-06-14 |
2023-06-15 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Kalif Eliyahu Sharon |
EVP, Chief Financial Officer |
|
2025-06-12 |
4 |
AS |
$17.08 |
$952,464 |
D/D |
(55,775) |
403,288 |
|
- |
|
Mignone Roberto |
|
|
2025-06-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,632 |
105,315 |
|
- |
|
Elstein Amir |
|
|
2025-06-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,632 |
2,103,963 |
|
- |
|
Crane Rosemary A |
|
|
2025-06-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,632 |
113,247 |
|
- |
|
Zaks Tal Zvi |
|
|
2025-06-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,632 |
58,772 |
|
- |
|
Vergis Janet S. |
|
|
2025-06-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,632 |
73,697 |
|
- |
|
Nisen Perry |
|
|
2025-06-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,632 |
105,315 |
|
- |
|
Shalev Varda |
|
|
2025-06-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,632 |
22,504 |
|
- |
|
Lieberman Gerald M |
|
|
2025-06-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,632 |
115,657 |
|
- |
|
Satchi-Fainaro Ronit |
|
|
2025-06-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,632 |
97,909 |
|
- |
|
Barer Sol J |
|
|
2025-06-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,158 |
426,272 |
|
- |
|
Shields Matthew |
EVP, Global Operations |
|
2025-06-03 |
4 |
S |
$17.02 |
$105,628 |
D/D |
(6,206) |
9,989 |
|
1% |
|
Shields Matthew |
EVP, Global Operations |
|
2025-06-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,195 |
16,195 |
|
- |
|
Sabag Mark |
See Remarks |
|
2025-05-08 |
4 |
S |
$18.04 |
$6,097,304 |
D/D |
(337,915) |
150,996 |
|
6% |
|
Kalif Eliyahu Sharon |
EVP, Chief Financial Officer |
|
2025-03-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,390 |
459,063 |
|
- |
|
Sabag Mark |
See Remarks |
|
2025-03-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,765 |
488,911 |
|
- |
|
Daniell Richard |
Exec. VP, European Commercial |
|
2025-03-05 |
4 |
AS |
$15.90 |
$1,128,642 |
D/D |
(70,961) |
48,384 |
|
7% |
|
Daniell Richard |
Exec. VP, European Commercial |
|
2025-03-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,576 |
119,345 |
|
- |
|
Weiss Amir |
Chief Accounting Officer |
|
2025-03-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,566 |
30,250 |
|
- |
|
Francis Richard D |
President and CEO |
|
2025-03-05 |
4 |
AS |
$15.91 |
$131,427 |
D/D |
(8,259) |
271,783 |
|
7% |
|
Hughes Eric A |
See Remarks |
|
2025-03-05 |
4 |
AS |
$15.91 |
$128,531 |
D/D |
(8,077) |
0 |
|
7% |
|
Daniell Richard |
Exec. VP, European Commercial |
|
2025-03-05 |
4 |
AS |
$15.91 |
$775,991 |
D/D |
(48,764) |
96,769 |
|
7% |
|
Mcavoy David R. |
EVP, Chief Legal Officer |
|
2025-03-05 |
4 |
AS |
$15.91 |
$26,686 |
D/D |
(1,677) |
11,914 |
|
7% |
|
Fox Christine |
EVP, Head of U.S. Commercial |
|
2025-03-05 |
4 |
AS |
$15.91 |
$34,166 |
D/D |
(2,147) |
58,384 |
|
7% |
|
Weiss Amir |
Chief Accounting Officer |
|
2025-03-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,326 |
26,684 |
|
- |
|
597 Records found
|
|
Page 1 of 24 |
|
|